<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03119558</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-35049</org_study_id>
    <nct_id>NCT03119558</nct_id>
  </id_info>
  <brief_title>PET/MRI Evaluation of Cardiac Amyloid</brief_title>
  <official_title>18F‑Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called
      amyloid in the heart tissue. This makes it difficult for the heart to function properly. The
      investigators wish to evaluate if the radiopharmaceutical 18F‑Florbetaben (Neuraceq®) that
      targets beta amyloid can also identify cardiac amyloid deposition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of hybrid positron emission tomography/ magnetic resonance imaging (PET/MRI) scanners
      in clinical practice enhance the ability to evaluate the heart from both an anatomical and
      functional perspective. It is hypothesized that an increased PET signal of 18F‑Florbetaben
      (Neuraceq®) will be detected in cardiac amyloid deposits within the heart tissue, while the
      MRI provides the anatomical information. The ability to reliably and non-invasively image
      amyloid deposition in the heart would be potentially advantageous in the following scenarios:

        1. Diagnosis of cardiac amyloidosis

        2. Decreasing unnecessary invasive myocardial procedures.

      The investigators believe this trial will help expand the use of current PET amyloid tracers
      and help many patients who currently undergo myocardial biopsy for the diagnosis of cardiac
      amyloid.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with 18F‑Florbetaben (Neuraceq®) uptake on Fused PET/MRI Images</measure>
    <time_frame>an estimated average of 2 hours</time_frame>
    <description>Diffuse (widespread), focal (point) and focal-on-diffuse (combination of the two) patterns of 18F-Florbetaben uptake will be considered positive findings indicating cardiac amyloidosis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>18F‑Florbetaben (Neuraceq®) PET/MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with known or suspected cardiac amyloidosis will be injected with 8 mCi of 18F‑Florbetaben (Neuraceq®) and undergo the PET/MRI image acquisition 45‑60 minute post-injection. PET and MRI data will be acquired simultaneously to ensure optimal timing and spatial correspondence between MRI and PET data. Total scan time will take approximately 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F‑Florbetaben (Neuraceq®) PET/MRI</intervention_name>
    <description>Administration of 8.0 mCi 18F‑Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.</description>
    <arm_group_label>18F‑Florbetaben (Neuraceq®) PET/MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is ≥ 18 years old at the time of the scan

          -  Patient with known or suspected cardiac amyloidosis.

          -  Patient is capable of complying with study procedures

        Exclusion Criteria:

          -  Patient is pregnant or nursing

          -  Metallic implants (contraindicated for MRI)

          -  History of renal insufficiency (only for MRI contrast administration)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Iagaru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Otte</last_name>
    <phone>(650) 736-4183</phone>
    <email>anotte@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lacey Greene, BS</last_name>
    <phone>6507254712</phone>
    <email>lacey.greene@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Otte</last_name>
      <phone>650-736-4183</phone>
      <email>anotte@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lacey Greene, BS</last_name>
      <phone>6507254712</phone>
      <email>lacey.greene@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Herfkens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrei Iagaru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrei Iagaru</investigator_full_name>
    <investigator_title>Associate Professor of Radiology - Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

